While reports have clearly demonstrated that pyrvinium allosterically activates CK1α to block Wnt/β-catenin signalling in colon cancer and hedgehog signalling in medulloblastomas respectively [15–17], others have shown that CK1α is not the bona-fide target of pyrvinium in transformed cells of the embryonic kidney (HEK293T) and leukemia origin [12, 13, 27]. Here, CSNK1A1 is linked to malignant colon neoplasm.